Categories
Anticancer Drugs Oncology Pharmacology Physiotherapy Sotorasib

Sotorasib and Interstitial Lung Disease

In this article we will discuss Sotorasib and Interstitial Lung Disease

In this article, we will discuss Sotorasib and Interstitial Lung Disease. So, let’s get started.

Sotorasib and Interstitial Lung Disease (ILD)/Pneumonitis

Sotorasib can cause ILD/pneumonitis that can be fatal. Among 357 patients who received Sotorasib in CodeBreaK 100, ILD/pneumonitis occurred in 0.8% of patients, all cases were
Grade 3 or 4 at onset, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 2 weeks (range: 2 to 18 weeks). Sotorasib was discontinued due to ILD/pneumonitis in 0.6% of patients. Monitor
patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever).
Immediately withhold Sotorasib in patients with suspected ILD/pneumonitis and permanently discontinue Sotorasib if no other potential causes of ILD/pneumonitis are identified.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.